^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IDH1 mutation + Chr del(1p) + Chr del(19q)

i
Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
Entrez ID:
Related biomarkers:
6ms
Clinical characteristics and prognostic factors of solitary and multiple adult gliomas: a retrospective study based on propensity score matching. (PubMed, Eur Rev Med Pharmacol Sci)
The prognosis for multiple gliomas is extremely poor, which is related to the fact that the most common pathological types are glioblastomas and the surgical procedure is challenging. Concurrent chemotherapy and radiotherapy are the strongest protective prognostic factors, and the differences in their molecular pathology expression compared to solitary gliomas remain for further investigation.
Retrospective data • Journal
|
TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NF1 (Neurofibromin 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
TP53 mutation • IDH1 mutation • NF1 mutation • MGMT promoter methylation • IDH1 mutation + Chr del(1p) + Chr del(19q) • TP53 expression
1year
Diffuse leptomeningeal glioneuronal tumor in a child masquerading as an intramedullary spinal pilocytic astrocytoma. (PubMed, Neurooncol Adv)
Despite the morphologic similarities to pilocytic astrocytoma and the lack of oligodendroglial/neuronal components or leptomeningeal dissemination, the molecular profile was definitive in classifying the tumor as DLGNT. This case highlights the importance of molecular and genetic testing in the characterization of pediatric central nervous system tumors.
Journal
|
BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • KIAA1549
|
BRAF mutation • IDH1 mutation • IDH1 mutation + Chr del(1p) + Chr del(19q) • KIAA1549-BRAF fusion • BRAF fusion
almost2years
Identifying Differential Expression Genes and Prognostic Signature Based on Subventricular Zone Involved Glioblastoma. (PubMed, Front Genet)
Here, a novel gene signature based on DEGs between GBM and healthy SVZ was developed for determining GBM patient prognosis. Targeting these genes may be a therapeutic strategy for GBM.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • BCAT1 (Branched Chain Amino Acid Transaminase 1 ) • NNMT (Nicotinamide N-Methyltransferase) • TNFRSF19 (TNF Receptor Superfamily Member 19)
|
PD-L1 expression • IDH1 mutation • IDH1 mutation + Chr del(1p) + Chr del(19q)